NYSE: JNJJohnson & Johnson Stock
$156.31+0.40 (+0.26%)
Updated Apr 30, 2025
JNJ Price
$156.31
Fair Value Price
N/A
Market Cap
$376.09B
52 Week Low
$140.68
52 Week High
$169.99
P/E
17.25x
P/B
4.81x
P/S
4.41x
PEG
1.94x
Dividend Yield
3.17%
Revenue
$89.33B
Earnings
$21.81B
Gross Margin
68.3%
Operating Margin
30.68%
Profit Margin
24.4%
Debt to Equity
1.48
Operating Cash Flow
$25B
Beta
0.27
Next Earnings
N/A
Ex-Dividend
May 27, 2025
Next Dividend
Jun 10, 2025
JNJ Overview
Johnson & Johnson manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases. Other offerings include oral care, baby care, beauty, over-the-counter pharmaceutical, women's health, and wound care products, as well as medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. It distributes its products to retailers, wholesalers, health care professionals, and hospitals. J&J was founded in 1886 and is headquartered in New Brunswick, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine JNJ's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
JNJ
Ranked#1 of 18
Ranked#1 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $106.54 | A | |
| $50.20 | A | |
| $113.49 | B |
Be the first to know about important JNJ news, forecast changes, insider trades & much more!
JNJ News
Overview
Due Diligence Score
–
Industry Average (40)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how JNJ scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
JNJ ($156.31) is trading above its intrinsic value of $79.97, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
JNJ is good value based on its earnings relative to its share price (17.25x), compared to the US market average (29.18x)
P/E vs Market Valuation
JNJ is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more JNJ due diligence checks available for Premium users.
Valuation
JNJ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
17.25x
Industry
54.95x
Market
29.18x
JNJ is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
JNJ is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
JNJ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.81x
Industry
6.33x
JNJ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
JNJ price to earnings growth (PEG)
For valuing profitable companies with growth potential
JNJ is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
JNJ's financial health
Profit margin
Revenue
$21.9B
Net Income
$11.0B
Profit Margin
50.2%
JNJ's Earnings (EBIT) of $27.41B... subscribe to Premium to read more.
Interest Coverage Financials
JNJ's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$193.7B
Liabilities
$115.6B
Debt to equity
1.48
JNJ's short-term assets ($71.55B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
JNJ's short-term assets ($71.55B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
JNJ's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
JNJ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$4.2B
Investing
-$297.0M
Financing
$10.4B
JNJ's operating cash flow ($24.78B)... subscribe to Premium to read more.
Debt Coverage Financials
JNJ vs General Drug Manufacturer Stocks
Johnson & Johnson Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.